Non-Small-Cell Lung Cancer Regression by SiRNA Delivered Through Exosomes That Display EGFR RNA Aptamer

Overview

Journal Nucleic Acid Ther

Specialties Biochemistry
Molecular Biology
Pharmacology

Date 2021 May 17

PMID 33999716

Citations 24

Authors

Zhefeng Li

Linlin Yang

Hongzhi Wang

Daniel W Binzel

Terence M Williams

Peixuan Guo

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer death in the United States. The development of drug resistance to commonly used chemotherapeutics in non-small-cell lung cancer (NSCLC) poses significant health risks and there is a dire need to improve patient outcomes. In this study, we report the use of RNA nanotechnology to display ligand on exosome that was loaded with small interfering RNA (siRNA) for NSCLC regression in animal trials. Cholesterol was used to anchor the ligand targeting epidermal growth factor receptor on exosomes that were loaded with siRNA to silence the antiapoptotic factor survivin. The cytosolic delivery of siRNA overcame the problem of endosome trapping, leading to potent gene knockdown, chemotherapy sensitization, and tumor regression, thus achieving a favorable IC of 20 nmol/kg siRNA encapsulated by exosome particles in the gene knockdown assessment.

Citing Articles

The role of RNA structural motifs in RNA-lipid raft interaction.

Manka R, Sapon K, Zaziablo J, Janas T, Czogalla A, Janas T Sci Rep. 2025; 15(1):6777.

PMID: 40000734 PMC: 11861254. DOI: 10.1038/s41598-025-91093-x.

Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction.

Bhullar A, Jin K, Shi H, Jones A, Hironaka D, Xiong G Mol Ther. 2024; 32(12):4467-4481.

PMID: 39369270 PMC: 11638871. DOI: 10.1016/j.ymthe.2024.09.034.

Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.

Ubanako P, Mirza S, Ruff P, Penny C Front Mol Biosci. 2024; 11:1447953.

PMID: 39355533 PMC: 11442288. DOI: 10.3389/fmolb.2024.1447953.

Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials.

Chen Y, Luh F, Ho Y, Yen Y J Biomed Sci. 2024; 31(1):67.

PMID: 38992695 PMC: 11238361. DOI: 10.1186/s12929-024-01055-0.

Cracking the Code: Enhancing Molecular Tools for Progress in Nanobiotechnology.

Avila Y, Rebolledo L, Skelly E, de Freitas Saito R, Wei H, Lilley D ACS Appl Bio Mater. 2024; 7(6):3587-3604.

PMID: 38833534 PMC: 11190997. DOI: 10.1021/acsabm.4c00432.

References

Abdelmawla S, Guo S, Zhang L, Pulukuri S, Patankar P, Conley P . Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther. 2011; 19(7):1312-22. PMC: 3129564. DOI: 10.1038/mt.2011.35. View

Ke W, Hong E, Saito R, Rangel M, Wang J, Viard M . RNA-DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF-κB in human cells. Nucleic Acids Res. 2018; 47(3):1350-1361. PMC: 6379676. DOI: 10.1093/nar/gky1215. View

Guo P, Erickson S, Anderson D . A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science. 1987; 236(4802):690-4. DOI: 10.1126/science.3107124. View

Zhang D, Lee H, Zhu Z, Minhas J, Jin Y . Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2016; 312(1):L110-L121. PMC: 5283929. DOI: 10.1152/ajplung.00423.2016. View

Yin H, Wang H, Li Z, Shu D, Guo P . RNA Micelles for the Systemic Delivery of Anti-miRNA for Cancer Targeting and Inhibition without Ligand. ACS Nano. 2018; 13(1):706-717. PMC: 6542267. DOI: 10.1021/acsnano.8b07948. View

Pirker R, Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R . Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373(9674):1525-31. DOI: 10.1016/S0140-6736(09)60569-9. View

El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Piao X, Wang H, Binzel D, Guo P . Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ. RNA. 2017; 24(1):67-76. PMC: 5733572. DOI: 10.1261/rna.063057.117. View

10.

Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P . Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Mol Ther. 2019; 27(7):1252-1261. PMC: 6612664. DOI: 10.1016/j.ymthe.2019.04.018. View

11.

Johnstone R, Mathew A, Mason A, Teng K . Exosome formation during maturation of mammalian and avian reticulocytes: evidence that exosome release is a major route for externalization of obsolete membrane proteins. J Cell Physiol. 1991; 147(1):27-36. DOI: 10.1002/jcp.1041470105. View

12.

Guo S, Xu C, Yin H, Hill J, Pi F, Guo P . Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 12(1):e1582. PMC: 6908753. DOI: 10.1002/wnan.1582. View

13.

Khisamutdinov E, Li H, Jasinski D, Chen J, Fu J, Guo P . Enhancing immunomodulation on innate immunity by shape transition among RNA triangle, square and pentagon nanovehicles. Nucleic Acids Res. 2014; 42(15):9996-10004. PMC: 4150753. DOI: 10.1093/nar/gku516. View

14.

Nordmeier S, Ke W, Afonin K, Portnoy V . Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs). Nanomedicine. 2020; 30:102285. PMC: 7680442. DOI: 10.1016/j.nano.2020.102285. View

15.

Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K . Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 2010; 70(24):10402-10. DOI: 10.1158/0008-5472.CAN-10-2438. View

16.

Sun D, Zhuang X, Zhang S, Deng Z, Grizzle W, Miller D . Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2012; 65(3):342-7. DOI: 10.1016/j.addr.2012.07.002. View

17.

Ueno T, Uehara S, Nakahata K, Okuyama H . Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma. Int J Oncol. 2016; 48(5):1847-54. DOI: 10.3892/ijo.2016.3438. View

18.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

19.

Esposito C, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A . A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One. 2011; 6(9):e24071. PMC: 3167817. DOI: 10.1371/journal.pone.0024071. View

20.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood M . Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4):341-5. DOI: 10.1038/nbt.1807. View